Work

Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer

Year: 2024

Type: article

Abstract: safety studies showed no signs of toxicity after LMTK3BP treatment, even at doses as high as 40 mg/kg. This study highlights LMTK3 as a predictor of patient clinical outcomes. More importantly, novel LMTK3BPs represent potential safe treatment options, either alone or in combination with therapies, for OC.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2024.200864

Authors: Ghassan M. Saed, Nicole M. Fletcher, Harvey Sharma, Axel Stenmark Tullberg, Ella Ittner, Toshima Z. Parris, Daniella Pettersson, Anikó Kovács, Elisabeth Werner Rönnerman, Pernilla Dahm-Kähler, Anna Portela, Pamela D. Garzone, Robert Morris, Khalil Helou

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Gothenburg, Sahlgrenska University Hospital, Xenopat SL (Spain), Samsung Semiconductor (United States), Fair Isaac Corporation (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900

OpenAlex ID: W4401890786

FWCI: 0.646

Cites: 30

Cited by: 2

Related to: 10